1️⃣9️⃣ May 🌷🪻🪷

World #IBD Day 💜 in Wrocław with
#J_elita part of EFCCA

All this to help and support #IBD patients 👧🏼👨🏽👵🏻 and remember that 👉🏻 ' IBD Has No Borders' 💕

#WorldIBDday2024
| 🐆 #Crohn #Colitis
Wroclaw

ESD effectiveness and safety as treatment option in high-risk colorectal colitis-associated neoplasia in IBD.
Data from the Endoscopic Resection Italian Network presented at #DDW2024 by roberta maselli

⁦… dedicated to millions of people affected worldwide … ⁦EFCCA⁩ #IBD #crohndisease #ulcerativecolitis #IBD hasNoBorders #worldibdday2024

#DDW2024 - let‘s go 🥳
Hoping for better weather in Washington.😎
Florian Rieder Remo Panaccione, MD, FRCPC Y-ECCO Axel Dignass Irina Blumenstein Tim Raine Raja Atreya Fernando Gomollón Paulo G. Kotze Taku Kobayashi Natalia Queiroz alessandro armuzzi Fernando Magro iris dotan Seb guticas

#CGH4ALL CGH

🔥Active IBD is associated w/ cardiovascular☠️

👁️S1P receptors exist on ♥️ & vascular endothelial cells

💊Ozanimod may cause bradycardia during induction phase

💠What is the overall safety profile for this S1P receptor modulator?

🔗doi.org/10.1016/j.cgh.…

#Re - #resection Rates and #Disease #Re currence in #CD - A Population-Based Study Using Individual-Level Patient Data Anja Poulsen Jakob Seidelin

academic.oup.com/ecco-jcc/advan…

In IBD, and in medicine in general, it is increasingly important to identify those actions that do not add value (and can harm) and concentrate our efforts on what benefits our patients. Let's avoid “too much medicine”
cghjournal.org/article/S1542-…

Alzheimer's disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis. #IBD .
GUTJournal_BMJ

pubmed.ncbi.nlm.nih.gov/38684238/

Y-ECCO Florian Rieder Fernando Gomollón

….. balancing benefit/risk on the single patient, then 3 hierarchical points.
Not necessary avoiding colectomy at any cost, indeed…. x.com/jonathansegal8…

… but always balancing benefit/risk on the single patient.
Dogmas in ASUC (descending order):
1) avoid mortality
2) avoid colectomy
3) reduce drug-related AEs and hospital stay

Delighted to see 🇬🇧 PANTS study 3 year extension data published in The Lancet Gastroenterology & Hepatology
🙏🏼 to the investigators and patients who participated
sciencedirect.com/science/articl…

⏺️Only 1/3 of those treated with TNFis remain in remission at 3years
⏺️Week 14 levels significant in reducing

Crohn's disease after surgery: Changes in post-operative management strategies over time and their impact on long-term re-operation rate: A retrospective multicentre real-world study onlinelibrary.wiley.com/doi/10.1111/ap… via alessandro armuzzi et al Seb

I think that all of them are important. And probably we have to understand better our at risk-of-recurrence criteria ….

Hot off the press, online on AP&T. Crohn’s disease after surgery: despite increased post-operative use of IMMs and anti-TNFα agents in the last two decades, the impact of these strategies on the risk of long-term re-operation rate has been modest onlinelibrary.wiley.com/doi/10.1111/ap…

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications. ⁦Gut Journal⁩ gut.bmj.com/content/early/…

SuperNacho!

LOTS of great opportunities to join ECCO committees & work with colleagues all around the world - our aim being to improve lives of patients living with IBD🌍

Check out link below & especially consider applying to young ECCO for all who are eligible👥

ecco-ibd.eu/about-ecco/ecc…

Deep dive on Standards of Care in IBD! #GEDII2024 concludes with an advanced course on the crucial topic of standardizing care for #IBD from both physician & patient perspectives!

Ensuring effective & consistent treatment while prioritizing patient needs.

See you next year!

Manuel Barreiro alessandro armuzzi Fernando Magro Paula Ministro francisco portela

Amazing dinner and better company in @gedii THANKS Fernando Magro Y-ECCO alessandro armuzzi